Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future

ABSTRACT Background Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinica...

Full description

Saved in:
Bibliographic Details
Published inJournal of gastroenterology and hepatology Vol. 40; no. 4; pp. 808 - 820
Main Authors Cameron, Karla, Nguyen, Anke L., Gibson, David J., Ward, Mark G., Sparrow, Miles P., Gibson, Peter R.
Format Journal Article
LanguageEnglish
Published Australia Wiley Subscription Services, Inc 01.04.2025
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ABSTRACT Background Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD). Methods A detailed literature search was performed. Results Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels. Conclusions Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making.
AbstractList ABSTRACT Background Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD). Methods A detailed literature search was performed. Results Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels. Conclusions Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making.
BackgroundCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).MethodsA detailed literature search was performed.ResultsAlbumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.ConclusionsUnderstanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making.
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD). A detailed literature search was performed. Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels. Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making.
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).BACKGROUNDCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).A detailed literature search was performed.METHODSA detailed literature search was performed.Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.RESULTSAlbumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making.CONCLUSIONSUnderstanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making.
Author Gibson, David J.
Sparrow, Miles P.
Ward, Mark G.
Gibson, Peter R.
Cameron, Karla
Nguyen, Anke L.
AuthorAffiliation 1 Department of Gastroenterology, School of Translational Medicine Monash University and Alfred Health Melbourne Victoria Australia
AuthorAffiliation_xml – name: 1 Department of Gastroenterology, School of Translational Medicine Monash University and Alfred Health Melbourne Victoria Australia
Author_xml – sequence: 1
  givenname: Karla
  orcidid: 0009-0009-0113-3941
  surname: Cameron
  fullname: Cameron, Karla
  organization: Monash University and Alfred Health
– sequence: 2
  givenname: Anke L.
  surname: Nguyen
  fullname: Nguyen, Anke L.
  organization: Monash University and Alfred Health
– sequence: 3
  givenname: David J.
  surname: Gibson
  fullname: Gibson, David J.
  organization: Monash University and Alfred Health
– sequence: 4
  givenname: Mark G.
  surname: Ward
  fullname: Ward, Mark G.
  organization: Monash University and Alfred Health
– sequence: 5
  givenname: Miles P.
  surname: Sparrow
  fullname: Sparrow, Miles P.
  organization: Monash University and Alfred Health
– sequence: 6
  givenname: Peter R.
  orcidid: 0000-0001-9108-1712
  surname: Gibson
  fullname: Gibson, Peter R.
  email: peter.gibson@monash.edu
  organization: Monash University and Alfred Health
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39894941$$D View this record in MEDLINE/PubMed
BookMark eNp1kV9LHDEUxYNY6rrtQ79ACfSlgqPJJJOZ-CJb_26RCqLPITNzx82SSTSZcdlvb3SttIXmJbnkdw_ncHbRtvMOEPpCyQFN53B5vzigopLFFppQzklGSy620YRUtMgko3IH7ca4JIRwUhYf0Q6TleSS0wlqb-DJwArPwmAaC0d4ZuuxNw5r1-L5EPGNt4DTPHed1X2vBx_W-IdfgcWnJoKOaed2Afjatvt4SI9fsNp_3X4ZzsdhDPAJfei0jfD57Z6iu_Oz25PL7Or6Yn4yu8oaTniRdVBrWnDKBCt4rpnQkpG6YTqvGM8JYylOK7qupC0UUNEGGKFlUdacdVrzlk3R8Ub3Yax7aBtwQ9BWPQTT67BWXhv1948zC3XvnxSlUiRxkRS-vykE_zhCHFRvYgPWagd-jIpRkVdcCp4n9Ns_6NKPwaV8iaoESd5SlCn6-qeldy-_G0jA3gZogo8xQPeOUKJe2lWpXfXabmIPN-zKWFj_H1Q_Ly43G89qKqNk
Cites_doi 10.1093/ecco-jcc/jjaa268
10.1097/DCR.0000000000002831
10.1111/jgh.14962
10.1136/gut.38.1.99
10.1007/BF02236563
10.1097/MIB.0000000000001043
10.1038/s42003-020-0903-7
10.2147/IJGM.S102819
10.1046/j.1523-1755.1999.00298.x
10.1093/ecco-jcc/jjz083
10.1084/jem.20021829
10.1093/ibd/izaa309
10.1136/bmjgast-2021-000662
10.1016/0895-4356(92)90081-W
10.1002/jpen.1451
10.1097/MEG.0000000000000548
10.1136/gut.35.2.231
10.1002/jgh3.12506
10.1093/ecco-jcc/jjz195
10.1007/s12630-018-1181-4
10.1111/apt.13243
10.1371/journal.pone.0241558
10.1097/MD.0000000000025200
10.2215/CJN.09670620
10.1002/jgh3.13059
10.1016/S0039-6060(05)80251-X
10.18632/oncotarget.24172
10.2214/ajr.136.5.883
10.1016/j.cgh.2014.07.041
10.1111/j.1399-6576.1981.tb01622.x
10.3748/wjg.v23.i45.8008
10.1016/0002-9378(70)90364-9
10.1002/hep.1840120517
10.1136/bcr-2020-238802
10.1053/j.gastro.2015.04.016
10.1093/ecco-jcc/jjae094
10.1113/jphysiol.1896.sp000596
10.12659/MSM.897460
10.5414/CPP48297
10.1097/01.MIB.0000173271.18319.53
10.1172/JCI105885
10.1002/jgh3.12017
10.1097/MCG.0000000000000884
10.1093/ibd/izab285
10.1093/ecco-jcc/jjaa042
10.1016/j.ultrasmedbio.2020.12.001
10.1016/j.cgh.2018.06.031
10.1097/MD.0000000000024925
10.1111/j.1365-2036.2004.01945.x
10.1016/S0140-6736(18)30840-7
10.1016/B978-012552110-9/50006-4
10.1093/ecco-jcc/jjy028
10.1002/jcph.2384
10.1148/radiology.135.3.7384460
10.1007/s10620-016-4089-2
10.1111/j.1440-1746.2004.03486.x
10.1155/2020/3467419
10.1186/s12876-022-02113-3
10.1016/j.cgh.2014.07.055
10.1097/MIB.0000000000000212
10.1111/j.1440-1746.1996.tb01377.x
10.1093/ibd/izaa088
10.3109/00365521.2016.1144781
10.1097/00003643-200310000-00003
10.1186/s12876-022-02271-4
10.1111/apt.13934
10.1186/cc6812
10.1093/ibd/izx055
10.1159/000437077
ContentType Journal Article
Copyright 2025 The Author(s). published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
2025. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2025 The Author(s). published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
– notice: 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
– notice: 2025. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
H94
K9.
7X8
5PM
DOI 10.1111/jgh.16895
DatabaseName Wiley Open Access Collection
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList
AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1746
EndPage 820
ExternalDocumentID PMC11968156
39894941
10_1111_jgh_16895
JGH16895
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Crohn's Colitis Australia
  funderid: Ferring Research Grant
– fundername: CSL Behring
– fundername: Monash University
– fundername: Crohn's Colitis Australia
  grantid: Ferring Research Grant
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
24P
29K
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
DU5
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KMS
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c4045-feba1541363542a36a930bc3a28342033815d6ff71de5e81ce301757b43faa4d3
IEDL.DBID DR2
ISSN 0815-9319
1440-1746
IngestDate Thu Aug 21 18:37:38 EDT 2025
Fri Jul 11 03:01:38 EDT 2025
Wed Aug 13 09:01:21 EDT 2025
Mon Jul 21 06:01:12 EDT 2025
Tue Jul 01 05:17:19 EDT 2025
Fri Apr 04 09:53:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords protein turnover
hypoalbuminaemia
albumin
Crohn's disease
nutritional assessment
ulcerative colitis
diagnostic test
therapeutic drug monitoring
Language English
License Attribution-NonCommercial-NoDerivs
2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4045-feba1541363542a36a930bc3a28342033815d6ff71de5e81ce301757b43faa4d3
Notes This work was supported by CSL Behring, Crohn's Colitis Australia (Ferring Research Grant), and Monash University.
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Funding: This work was supported by CSL Behring, Crohn's Colitis Australia (Ferring Research Grant), and Monash University.
ORCID 0009-0009-0113-3941
0000-0001-9108-1712
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.16895
PMID 39894941
PQID 3186030141
PQPubID 2045136
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11968156
proquest_miscellaneous_3162849642
proquest_journals_3186030141
pubmed_primary_39894941
crossref_primary_10_1111_jgh_16895
wiley_primary_10_1111_jgh_16895_JGH16895
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2025
PublicationDateYYYYMMDD 2025-04-01
PublicationDate_xml – month: 04
  year: 2025
  text: April 2025
PublicationDecade 2020
PublicationPlace Australia
PublicationPlace_xml – name: Australia
– name: Richmond
– name: Hoboken
PublicationTitle Journal of gastroenterology and hepatology
PublicationTitleAlternate J Gastroenterol Hepatol
PublicationYear 2025
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2021; 27
2017; 1
1990; 12
2015; 149
2019; 13
2000; 43
2015; 33
2017; 45
2019; 17
2020; 15
2011; 11
2020; 14
2018; 41
2022; 22
1996; 38
2022; 28
2003; 197
1980; 135
2014; 20
2018; 9
2020; 3
2024; 8
2015; 42
1999; 55
1994; 35
2024; 64
2024; 67
1992; 45
1968; 47
2015; 13
2021; 47
2021; 8
2021; 5
2017; 23
1995; 117
1981; 25
2008; 12
1995
2016; 51
2020; 35
2021; 100
2018; 65
1970; 106
2024; 18
1996; 11
2018; 24
2021; 14
2021; 16
2010; 42
2021; 15
2018; 391
2010; 48
2020; 2020
2023
2004; 19
2019; 43
1981; 136
2017; 55
2018; 52
2016; 61
2018; 12
2016; 28
2003; 20
2005; 11
2016; 9
1896; 19
2016; 22
e_1_2_14_73_1
e_1_2_14_75_1
e_1_2_14_31_1
e_1_2_14_52_1
e_1_2_14_50_1
e_1_2_14_71_1
e_1_2_14_10_1
e_1_2_14_56_1
Fulks M. (e_1_2_14_8_1) 2010; 42
e_1_2_14_12_1
e_1_2_14_33_1
e_1_2_14_54_1
e_1_2_14_14_1
e_1_2_14_39_1
e_1_2_14_16_1
e_1_2_14_37_1
e_1_2_14_58_1
e_1_2_14_6_1
e_1_2_14_60_1
e_1_2_14_2_1
e_1_2_14_41_1
e_1_2_14_64_1
e_1_2_14_20_1
e_1_2_14_4_1
e_1_2_14_62_1
e_1_2_14_45_1
Mokhele N. (e_1_2_14_48_1) 2017; 55
e_1_2_14_68_1
e_1_2_14_24_1
e_1_2_14_43_1
e_1_2_14_66_1
e_1_2_14_22_1
e_1_2_14_28_1
e_1_2_14_49_1
e_1_2_14_26_1
e_1_2_14_47_1
e_1_2_14_19_1
Fukunaga S. (e_1_2_14_35_1) 2018; 41
e_1_2_14_72_1
e_1_2_14_74_1
e_1_2_14_30_1
e_1_2_14_53_1
e_1_2_14_51_1
e_1_2_14_70_1
e_1_2_14_11_1
e_1_2_14_34_1
e_1_2_14_57_1
e_1_2_14_13_1
e_1_2_14_32_1
e_1_2_14_55_1
Roberts I. (e_1_2_14_23_1) 2011; 11
e_1_2_14_15_1
e_1_2_14_38_1
e_1_2_14_76_1
e_1_2_14_17_1
e_1_2_14_36_1
e_1_2_14_59_1
e_1_2_14_29_1
e_1_2_14_5_1
e_1_2_14_7_1
e_1_2_14_9_1
e_1_2_14_42_1
e_1_2_14_63_1
e_1_2_14_3_1
e_1_2_14_40_1
e_1_2_14_61_1
e_1_2_14_46_1
e_1_2_14_67_1
e_1_2_14_21_1
e_1_2_14_44_1
e_1_2_14_27_1
e_1_2_14_25_1
e_1_2_14_69_1
Choy M. C. (e_1_2_14_65_1) 2024; 18
e_1_2_14_18_1
References_xml – volume: 45
  start-page: 213
  issue: 3
  year: 1992
  end-page: 221
  article-title: Serum Albumin in Older Persons: Relationship With Age and Health Status
  publication-title: Journal of Clinical Epidemiology
– volume: 28
  start-page: e10
  issue: 3
  year: 2016
  end-page: e18
  article-title: The Clinical Management of Abdominal Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: A Review of Current Guidelines and Recommendations
  publication-title: European Journal of Gastroenterology & Hepatology
– volume: 135
  start-page: 713
  issue: 3
  year: 1980
  end-page: 716
  article-title: Ultrasonographic Evidence of Gallbladder Wall Thickening in Association With Hypoalbuminemia
  publication-title: Radiology
– volume: 67
  start-page: 97
  issue: 1
  year: 2024
  end-page: 106
  article-title: Impact of Preoperative Factors in Patients With IBD on Postoperative Length of Stay: A National Surgical Quality Improvement Program‐Inflammatory Bowel Disease Collaborative Analysis
  publication-title: Diseases of the Colon and Rectum
– volume: 197
  start-page: 315
  issue: 3
  year: 2003
  end-page: 322
  article-title: The Major Histocompatibility Complex‐Related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan
  publication-title: Journal of Experimental Medicine
– volume: 65
  start-page: 1218
  issue: 11
  year: 2018
  end-page: 1227
  article-title: Association Between Albumin Administration and Survival in Cardiac Surgery: A Retrospective Cohort Study
  publication-title: Canadian Journal of Anaesthesia
– volume: 43
  start-page: 181
  issue: 2
  year: 2019
  end-page: 193
  article-title: Hypoalbuminemia: Pathogenesis and Clinical Significance
  publication-title: Journal of Parenteral and Enteral Nutrition
– volume: 38
  start-page: 99
  year: 1996
  end-page: 103
  article-title: Microalbuminuria Correlates With Intestinal Histopathological Grading in Patients With Inflammatory Bowel Disease
  publication-title: Gut
– volume: 47
  start-page: 1958
  issue: 9
  year: 1968
  end-page: 1972
  article-title: Albumin Metabolism: Effect of the Nutritional State and the Dietary Protein Intake
  publication-title: Journal of Clinical Investigation
– volume: 14
  start-page: 1231
  year: 2020
  end-page: 1240
  article-title: Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti‐Tumour Necrosis Factor Therapy
  publication-title: Journal of Crohn's & Colitis
– volume: 23
  start-page: 8008
  issue: 45
  year: 2017
  end-page: 8016
  article-title: Albumin as a Prognostic Marker for Ulcerative Colitis
  publication-title: World Journal of Gastroenterology
– volume: 64
  start-page: 399
  issue: 4
  year: 2024
  end-page: 409
  article-title: Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis
  publication-title: Journal of Clinical Pharmacology
– volume: 5
  start-page: 377
  issue: 3
  year: 2021
  end-page: 381
  article-title: Low Serum Albumin at Admission Is a Predictor of Early Colectomy in Patients With Moderate to Severe Ulcerative Colitis
  publication-title: JGH Open
– volume: 43
  start-page: 1141
  issue: 8
  year: 2000
  end-page: 1145
  article-title: Risk Factors for Intra‐Abdominal Sepsis After Surgery in Crohn's Disease
  publication-title: Diseases of the Colon and Rectum
– volume: 61
  start-page: 2051
  issue: 7
  year: 2016
  end-page: 2059
  article-title: Long‐Term Follow‐Up of Patients Treated With Infliximab for Ulcerative Colitis: Predictive Factors of Response‐An Observational Study
  publication-title: Digestive Diseases and Sciences
– volume: 25
  start-page: 125
  year: 1981
  end-page: 132
  article-title: Albumin Treatment Following Major Surgery. Effects on Plasma Oncotic Pressure, Renal Function and Peripheral Oedema
  publication-title: Acta Anaesthesiologica Scandinavica
– volume: 47
  start-page: 1108
  issue: 4
  year: 2021
  end-page: 1114
  article-title: Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study
  publication-title: Ultrasound in Medicine & Biology
– volume: 9
  start-page: 13934
  issue: 17
  year: 2018
  end-page: 13947
  article-title: Clinicopathologic and Prognostic Significance of C‐Reactive Protein/Albumin Ratio in Patients With Solid Tumours: An Updated Systematic Review and meta Analysis
  publication-title: Oncotarget
– volume: 3
  start-page: 181
  issue: 1
  year: 2020
  article-title: An Intact C‐Terminal end of Albumin Is Required for Its Long Half‐Life in Humans
  publication-title: Communications Biology
– volume: 1
  start-page: 98
  issue: 3
  year: 2017
  end-page: 104
  article-title: Blood Biomarkers Reflect Integration of Severity and Extent of Endoscopic Inflammation in Ulcerative Colitis
  publication-title: JGH Open
– volume: 18
  issue: January 2024
  year: 2024
  article-title: P872 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis—A Randomised Controlled Trial
  publication-title: Journal of Crohn's and Colitis
– volume: 33
  start-page: 61
  issue: Suppl 1
  year: 2015
  end-page: 69
  article-title: The Pharmacokinetics of Biologics: A Primer
  publication-title: Digestive Diseases
– volume: 18
  start-page: 1870
  year: 2024
  end-page: 1878
  article-title: Intravenous Albumin Infusion Does Not Augment the Response Rate to a Combination of Exclusive Enteral Nutrition and Intravenous Steroids in Acute Severe Ulcerative Colitis: A Randomized Controlled Trial
  publication-title: Journal of Crohn's & Colitis
– volume: 14
  start-page: 694
  issue: 5
  year: 2020
  end-page: 709
  article-title: Predictors of Primary Response to Biologic Treatment [Anti‐TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
  publication-title: Journal of Crohn's & Colitis
– volume: 41
  start-page: 107
  issue: 1
  year: 2018
  end-page: 118
  article-title: Detection of Calprotectin in Inflammatory Bowel Disease: Fecal and Serum Levels and Immunohistochemical Localization
  publication-title: International Journal of Molecular Medicine
– volume: 15
  start-page: 1142
  issue: 7
  year: 2021
  end-page: 1151
  article-title: Hypoalbuminaemia, Not Biologic Exposure, Is Associated With Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection
  publication-title: Journal of Crohn's & Colitis
– volume: 22
  start-page: 39
  issue: 1
  year: 2022
  article-title: Effect of Disease Duration on the Association Between C‐Reactive Protein‐Albumin Ratio and Endoscopic Activity in Ulcerative Colitis
  publication-title: BMC Gastroenterology
– volume: 391
  start-page: 2417
  issue: 10138
  year: 2018
  end-page: 2429
  article-title: Long‐Term Albumin Administration in Decompensated Cirrhosis (ANSWER): An Open‐Label Randomised Trial
  publication-title: Lancet
– volume: 100
  issue: 10
  year: 2021
  article-title: C‐Reactive Protein/Abumin Ratio Is a Useful Biomarker for Predicting the Mucosal Healing in the Crohn Disease: A Retrospective Study
  publication-title: Medicine (Baltimore)
– volume: 52
  start-page: e48
  issue: 6
  year: 2018
  end-page: e52
  article-title: CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis
  publication-title: Journal of Clinical Gastroenterology
– volume: 13
  start-page: 531
  year: 2015
  end-page: 538
  article-title: A Panel to Predict Long‐Term Outcome of Infliximab Therapy for Pateints With Ulcerative Colitis
  publication-title: Clinical Gastroenterology and Hepatology
– volume: 9
  start-page: 229
  year: 2016
  end-page: 255
  article-title: Human Serum Albumin Homeostasis: A New Look at the Roles of Synthesis, Catabolism, Renal and Gastrointestinal Excretion, and the Clinical Value of Serum Albumin Measurements
  publication-title: International Journal of General Medicine
– volume: 48
  start-page: 297
  issue: 5
  year: 2010
  end-page: 308
  article-title: Serum Albumin Concentration: A Predictive Factor of Infliximab Pharmacokinetics and Clinical Response in Patients With Ulcerative Colitis
  publication-title: International Journal of Clinical Pharmacology and Therapeutics
– volume: 13
  start-page: 1433
  issue: 11
  year: 2019
  end-page: 1438
  article-title: Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: The NSQIP Surgical Cohort
  publication-title: Journal of Crohn's & Colitis
– volume: 149
  start-page: 350
  issue: 2
  year: 2015
  end-page: 355
  article-title: Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
  publication-title: Gastroenterology
– volume: 28
  start-page: 1375
  year: 2022
  end-page: 1385
  article-title: Dashboard‐Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
  publication-title: Inflammatory Bowel Diseases
– volume: 12
  start-page: 1179
  issue: 5
  year: 1990
  end-page: 1186
  article-title: Acute‐Phase Response of Human Hepatocytes: Regulation of Acute‐Phase Protein Synthesis by Interleukin‐6
  publication-title: Hepatology
– volume: 11
  start-page: 311
  year: 1996
  end-page: 318
  article-title: Measurement of Faecal Alpha 1‐Antitrypsin: Methodologies and Clinical Application
  publication-title: Journal of Gastroenterology and Hepatology
– volume: 117
  start-page: 520
  issue: 5
  year: 1995
  end-page: 530
  article-title: Hepatic Metabolic Response to Injury and sepsis
  publication-title: Surgery
– volume: 20
  start-page: 771
  issue: 10
  year: 2003
  end-page: 793
  article-title: Albumin Administration—What Is the Evidence of Clinical Benefit? A Systematic Review of Randomized Controlled Trials
  publication-title: European Journal of Anaesthesiology
– volume: 27
  start-page: 451
  issue: 4
  year: 2021
  end-page: 457
  article-title: The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission That Predicts Outcome in Patients With Acute Ulcerative Colitis
  publication-title: Inflammatory Bowel Diseases
– volume: 19
  start-page: 1247
  year: 2004
  end-page: 1252
  article-title: Severe Ulcerative Colitis: Prospective Study of Parameters Determining Outcome
  publication-title: Journal of Gastroenterology and Hepatology
– volume: 23
  start-page: 650
  issue: 4
  year: 2017
  end-page: 660
  article-title: A Real‐Life Population Pharmacokinetic Study Reveals Factors Associated With Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
  publication-title: Inflammatory Bowel Diseases
– volume: 51
  start-page: 934
  issue: 8
  year: 2016
  end-page: 941
  article-title: Prediction of Clinical and Endoscopic Responses to Anti‐Tumor Necrosis Factor‐Alpha Antibodies in Ulcerative Colitis
  publication-title: Scandinavian Journal of Gastroenterology
– volume: 136
  start-page: 883
  year: 1981
  end-page: 886
  article-title: Radiologic Features of the Jejunum in Hypoalbuminemia
  publication-title: American Journal of Roentgenology
– volume: 27
  start-page: 1452
  issue: 9
  year: 2021
  end-page: 1461
  article-title: Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti‐TNF Treatment
  publication-title: Inflammatory Bowel Diseases
– volume: 13
  start-page: 330
  issue: 2
  year: 2015
  end-page: 335
  article-title: An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
  publication-title: Clinical Gastroenterology and Hepatology
– volume: 14
  start-page: 1
  year: 2021
  end-page: 5
  article-title: Protein‐Losing Enteropathy as Precursor of Inflammtory Bowel Disease: A Review of the Literature
  publication-title: BMJ Case Reports
– volume: 100
  issue: 14
  year: 2021
  article-title: Accuracy of the Highly Sensitive C‐Reactive Protein/Albumin Ratio to Determine Disease Activity in Inflammatory Bowel Disease
  publication-title: Medicine (Baltimore)
– volume: 55
  start-page: 629
  issue: 2
  year: 1999
  end-page: 634
  article-title: Coadministration of Albumin and Furosemide in Patients With the Nephrotic Syndrome
  publication-title: Kidney International
– volume: 20
  start-page: 2247
  issue: 12
  year: 2014
  end-page: 2259
  article-title: Patient Factors That Increase Infliximab Clearance and Shorten Half‐Life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
  publication-title: Inflammatory Bowel Diseases
– volume: 12
  start-page: 662
  issue: 6
  year: 2018
  end-page: 669
  article-title: Accelerated Clearance of Infliximab Is Associated With Treatment Failure in Patients With Corticosteroid‐Refractory Acute Ulcerative Colitis
  publication-title: Journal of Crohn's & Colitis
– volume: 16
  start-page: 820
  issue: 5
  year: 2021
  end-page: 828
  article-title: Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration During Kidney Replacement Therapy
  publication-title: Clinical Journal of the American Society of Nephrology
– volume: 35
  start-page: 1163
  issue: 7
  year: 2020
  end-page: 1170
  article-title: Clinical Relevance of Innovative Immunoassays for Serum Ustekinumab and Anti‐Ustekinumab Antibody Levels in Crohn's Disease
  publication-title: Journal of Gastroenterology and Hepatology
– volume: 22
  start-page: 195
  issue: 1
  year: 2022
  article-title: Ustekinumab Trough Levels Predicting Laboratory and Endoscopic Remission in Patients With Crohn's Disease
  publication-title: BMC Gastroenterology
– volume: 15
  issue: 11
  year: 2020
  article-title: Commonly Used Clinical Chemistry Tests as Mortality Predictors: Results From Two Large Cohort Studies
  publication-title: PLoS ONE
– volume: 19
  start-page: 1079
  issue: 10
  year: 2004
  end-page: 1087
  article-title: Predicting the Outcome of Severe Ulcerative Colitis: Development of a Novel Risk Score to aid Early Selection of Patients for Second‐Line Medical Therapy or Surgery
  publication-title: Alimentary Pharmacology & Therapeutics
– volume: 24
  start-page: 839
  issue: 4
  year: 2018
  end-page: 848
  article-title: Fecal Calprotectin During Pregnancy in Women With Moderate‐Severe Inflammatory Bowel Disease
  publication-title: Inflammatory Bowel Diseases
– volume: 106
  start-page: 388
  issue: 3
  year: 1970
  end-page: 399
  article-title: Serum Protein Concentrations in Pregnancy. 1. Concentrations in Maternal Serum
  publication-title: American Journal of Obstetrics and Gynecology
– volume: 8
  issue: 4
  year: 2024
  article-title: Clinical Utility of C‐Reactive Protein‐To‐Albumin Ratio in the Management of Patients With Inflammatory Bowel Disease
  publication-title: JGH Open
– volume: 12
  start-page: R34
  issue: 2
  year: 2008
  article-title: Small‐Volume Resuscitation With Hyperoncotic Albumin: A Systematic Review of Randomized Clinical Trials
  publication-title: Critical Care
– volume: 22
  start-page: 4393
  year: 2016
  end-page: 4400
  article-title: Serum Albumin and C‐Reactive Protein/Albumin Ratio Are Useful Biomarkers of Crohn's Disease Activity
  publication-title: Medical Science Monitor
– volume: 19
  start-page: 312
  issue: 4
  year: 1896
  end-page: 326
  article-title: On the Absorption of Fluids From the Connective Tissue Spaces
  publication-title: Journal of Physiology
– year: 2023
– volume: 8
  issue: 1
  year: 2021
  article-title: Effect of Disease Duration on the Association Between Serum Albumin and Mucosal Healing in Patients With Ulcerative Colitis
  publication-title: BMJ Open Gastroenterology
– year: 1995
– volume: 42
  start-page: 11
  year: 2010
  end-page: 17
  article-title: Albumin and All‐Cause Mortality Risk in Insurance Applicants
  publication-title: Journal of Insurance Medicine
– volume: 55
  start-page: 20
  issue: 3
  year: 2017
  end-page: 26
  article-title: Predictors of Emergency Colectomy in Patients Admitted With Acute Severe Ulcerative Colitis
  publication-title: South African Journal of Surgery
– volume: 45
  start-page: 660
  issue: 5
  year: 2017
  end-page: 669
  article-title: Exclusive Enteral Nutrition Provides an Effective Bridge to Safer Interval Elective Surgery for Adults With Crohn's Disease
  publication-title: Alimentary Pharmacology & Therapeutics
– volume: 11
  year: 2011
  article-title: Human Albumin Solution for Resuscitation and Volume Expansion in Critically Ill Patients
  publication-title: Cochrane Database of Systematic Reviews
– volume: 2020
  year: 2020
  article-title: The Relationship Between C‐Reactive Protein/Albumin Ratio and Disease Activity in Patients With Inflammatory Bowel Disease
  publication-title: Gastroenterology Research and Practice
– volume: 11
  start-page: 707
  issue: 8
  year: 2005
  end-page: 712
  article-title: Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease
  publication-title: Inflammatory Bowel Diseases
– volume: 42
  start-page: 188
  issue: 2
  year: 2015
  end-page: 202
  article-title: Population Pharmacokinetics‐Pharmacodynamics of Vedolizumab in Patients With Ulcerative Colitis and Crohn's Disease
  publication-title: Alimentary Pharmacology & Therapeutics
– volume: 35
  start-page: 231
  year: 1994
  end-page: 235
  article-title: Correlations Between Clinical Activity, Endoscopic Severity, and Biological Parameters in Colonic or Ileocolonic Crohn's Disease. A Prospective Multicentre Study of 121 Cases
  publication-title: Gut
– volume: 17
  start-page: 502
  issue: 3
  year: 2019
  end-page: 509
  article-title: Effect of Accelerated Infliximab Induction on Short‐ and Long‐Term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta‐Analysis
  publication-title: Clinical Gastroenterology and Hepatology
– ident: e_1_2_14_51_1
  doi: 10.1093/ecco-jcc/jjaa268
– ident: e_1_2_14_49_1
  doi: 10.1097/DCR.0000000000002831
– ident: e_1_2_14_71_1
  doi: 10.1111/jgh.14962
– ident: e_1_2_14_28_1
  doi: 10.1136/gut.38.1.99
– ident: e_1_2_14_52_1
  doi: 10.1007/BF02236563
– ident: e_1_2_14_58_1
  doi: 10.1097/MIB.0000000000001043
– ident: e_1_2_14_22_1
  doi: 10.1038/s42003-020-0903-7
– ident: e_1_2_14_2_1
  doi: 10.2147/IJGM.S102819
– ident: e_1_2_14_18_1
  doi: 10.1046/j.1523-1755.1999.00298.x
– ident: e_1_2_14_50_1
  doi: 10.1093/ecco-jcc/jjz083
– ident: e_1_2_14_4_1
  doi: 10.1084/jem.20021829
– ident: e_1_2_14_64_1
  doi: 10.1093/ibd/izaa309
– ident: e_1_2_14_39_1
  doi: 10.1136/bmjgast-2021-000662
– ident: e_1_2_14_5_1
  doi: 10.1016/0895-4356(92)90081-W
– ident: e_1_2_14_9_1
  doi: 10.1002/jpen.1451
– ident: e_1_2_14_16_1
  doi: 10.1097/MEG.0000000000000548
– ident: e_1_2_14_31_1
  doi: 10.1136/gut.35.2.231
– ident: e_1_2_14_42_1
  doi: 10.1002/jgh3.12506
– ident: e_1_2_14_61_1
  doi: 10.1093/ecco-jcc/jjz195
– volume: 18
  issue: 2024
  year: 2024
  ident: e_1_2_14_65_1
  article-title: P872 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis—A Randomised Controlled Trial
  publication-title: Journal of Crohn's and Colitis
– ident: e_1_2_14_20_1
  doi: 10.1007/s12630-018-1181-4
– ident: e_1_2_14_69_1
  doi: 10.1111/apt.13243
– ident: e_1_2_14_7_1
  doi: 10.1371/journal.pone.0241558
– ident: e_1_2_14_34_1
  doi: 10.1097/MD.0000000000025200
– ident: e_1_2_14_19_1
  doi: 10.2215/CJN.09670620
– ident: e_1_2_14_56_1
  doi: 10.1002/jgh3.13059
– ident: e_1_2_14_14_1
  doi: 10.1016/S0039-6060(05)80251-X
– ident: e_1_2_14_54_1
  doi: 10.18632/oncotarget.24172
– ident: e_1_2_14_13_1
  doi: 10.2214/ajr.136.5.883
– ident: e_1_2_14_46_1
  doi: 10.1016/j.cgh.2014.07.041
– ident: e_1_2_14_24_1
  doi: 10.1111/j.1399-6576.1981.tb01622.x
– ident: e_1_2_14_40_1
  doi: 10.3748/wjg.v23.i45.8008
– ident: e_1_2_14_6_1
  doi: 10.1016/0002-9378(70)90364-9
– ident: e_1_2_14_15_1
  doi: 10.1002/hep.1840120517
– ident: e_1_2_14_27_1
  doi: 10.1136/bcr-2020-238802
– volume: 55
  start-page: 20
  issue: 3
  year: 2017
  ident: e_1_2_14_48_1
  article-title: Predictors of Emergency Colectomy in Patients Admitted With Acute Severe Ulcerative Colitis
  publication-title: South African Journal of Surgery
– ident: e_1_2_14_66_1
  doi: 10.1053/j.gastro.2015.04.016
– ident: e_1_2_14_75_1
  doi: 10.1093/ecco-jcc/jjae094
– ident: e_1_2_14_11_1
  doi: 10.1113/jphysiol.1896.sp000596
– ident: e_1_2_14_30_1
  doi: 10.12659/MSM.897460
– ident: e_1_2_14_60_1
  doi: 10.5414/CPP48297
– volume: 11
  year: 2011
  ident: e_1_2_14_23_1
  article-title: Human Albumin Solution for Resuscitation and Volume Expansion in Critically Ill Patients
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_14_38_1
  doi: 10.1097/01.MIB.0000173271.18319.53
– ident: e_1_2_14_10_1
  doi: 10.1172/JCI105885
– ident: e_1_2_14_37_1
  doi: 10.1002/jgh3.12017
– ident: e_1_2_14_44_1
  doi: 10.1097/MCG.0000000000000884
– ident: e_1_2_14_72_1
  doi: 10.1093/ibd/izab285
– ident: e_1_2_14_32_1
  doi: 10.1093/ecco-jcc/jjaa042
– ident: e_1_2_14_57_1
  doi: 10.1016/j.ultrasmedbio.2020.12.001
– ident: e_1_2_14_74_1
  doi: 10.1016/j.cgh.2018.06.031
– ident: e_1_2_14_33_1
  doi: 10.1097/MD.0000000000024925
– ident: e_1_2_14_76_1
– ident: e_1_2_14_47_1
  doi: 10.1111/j.1365-2036.2004.01945.x
– ident: e_1_2_14_17_1
  doi: 10.1016/S0140-6736(18)30840-7
– ident: e_1_2_14_3_1
  doi: 10.1016/B978-012552110-9/50006-4
– ident: e_1_2_14_68_1
  doi: 10.1093/ecco-jcc/jjy028
– ident: e_1_2_14_73_1
  doi: 10.1002/jcph.2384
– ident: e_1_2_14_12_1
  doi: 10.1148/radiology.135.3.7384460
– ident: e_1_2_14_63_1
  doi: 10.1007/s10620-016-4089-2
– ident: e_1_2_14_43_1
  doi: 10.1111/j.1440-1746.2004.03486.x
– ident: e_1_2_14_36_1
  doi: 10.1155/2020/3467419
– ident: e_1_2_14_55_1
  doi: 10.1186/s12876-022-02113-3
– ident: e_1_2_14_41_1
  doi: 10.1016/j.cgh.2014.07.055
– ident: e_1_2_14_59_1
  doi: 10.1097/MIB.0000000000000212
– ident: e_1_2_14_26_1
  doi: 10.1111/j.1440-1746.1996.tb01377.x
– ident: e_1_2_14_45_1
  doi: 10.1093/ibd/izaa088
– ident: e_1_2_14_62_1
  doi: 10.3109/00365521.2016.1144781
– ident: e_1_2_14_21_1
  doi: 10.1097/00003643-200310000-00003
– ident: e_1_2_14_70_1
  doi: 10.1186/s12876-022-02271-4
– ident: e_1_2_14_53_1
  doi: 10.1111/apt.13934
– volume: 41
  start-page: 107
  issue: 1
  year: 2018
  ident: e_1_2_14_35_1
  article-title: Detection of Calprotectin in Inflammatory Bowel Disease: Fecal and Serum Levels and Immunohistochemical Localization
  publication-title: International Journal of Molecular Medicine
– volume: 42
  start-page: 11
  year: 2010
  ident: e_1_2_14_8_1
  article-title: Albumin and All‐Cause Mortality Risk in Insurance Applicants
  publication-title: Journal of Insurance Medicine
– ident: e_1_2_14_25_1
  doi: 10.1186/cc6812
– ident: e_1_2_14_29_1
  doi: 10.1093/ibd/izx055
– ident: e_1_2_14_67_1
  doi: 10.1159/000437077
SSID ssj0004075
Score 2.4517674
SecondaryResourceType review_article
Snippet ABSTRACT Background Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and...
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of...
BackgroundCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 808
SubjectTerms Albumin
Biomarkers - blood
Crohn's disease
Decision making
diagnostic test
Fc receptors
Hepatocytes
Homeostasis
Humans
hypoalbuminaemia
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory Bowel Diseases - blood
Inflammatory Bowel Diseases - diagnosis
Inflammatory Bowel Diseases - physiopathology
Inflammatory Bowel Diseases - therapy
Intestine
Malnutrition
Neonates
Nutrition Assessment
nutritional assessment
Pathophysiology
Physiology
Prognosis
protein turnover
Review
Serum Albumin - metabolism
Serum Albumin - physiology
Serum levels
therapeutic drug monitoring
Ulcerative colitis
Title Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.16895
https://www.ncbi.nlm.nih.gov/pubmed/39894941
https://www.proquest.com/docview/3186030141
https://www.proquest.com/docview/3162849642
https://pubmed.ncbi.nlm.nih.gov/PMC11968156
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD7qeEC8sMEGC4PKm_awB1I19aUxe9oGXVupG0Ig8YAU2bFD0boUra0m7dfv2LmspUJCe0sUW76ciz_7HH8BeN9RlDKXPZWlUodMsyhUSmYhs1pag4g-9vTFo2-if8WG1_y6AR-ruzAFP0R94OYsw_trZ-BKz5aN_HbcikQs3QVzl6vlANHFP-ooVpDsYls8lKhnJauQz-Kpaq6uRWsAcz1Pchm_-gWo9xxuqq4XeSc_Wou5bqV_HrA6_ufYXsB2CUzJp0KTdqBh813YHJWh95dgiihCVeCE-MP9u5yo3JDBfEYuphNL8H2QZ6hlP330nnye_rYTclpEgU4IKiX5PjHHBGEnQf967Gu7l57nNnkFV72zyy_9sPxFQ5gyBINhZrVCEIbzTzlDuQslaVunVCFqYZ027n8jbkSWdSNjuY2j1KJD6fKuZjRTihm6Bxv5NLevgfDUCqlUKhBTMoGjpyKNOaeZoVgtMgG8q4SV3BdMHEm9g7kdJ36-AjisxJiUxjhL0G0Jv3WMAnhbf0YzcrERldvpwpURuFBL3I0FsF9IvW6FOpJ66WrHK_pQF3AU3atf8ruxp-qO0ME5Pp4APnh5P97zZPi17x8Onl70DWx13O-IfSLRIWzMfy3sEWKkuW7Csw47b3qT-AscYgwi
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD5iIG172diAEW7z0B54IBWuL40RL9y6FihICCReUOTEDkV06TRaIfHrd-xcRoeQ0N4SxZadnIu_43PyGeB7UzPGXfVUlqok5AmnodYqC7lNlDWI6CNPX9w7lZ1LfnQlrqZgp_oXpuCHqDfcnGV4f-0M3G1IP7Xym36DykiJNzDjTvT2AdX5X_IoXtDs4mgiVKhpJa-Qr-Opuk6uRs8g5vNKyacI1i9B7Y9wXU2-qDy5a4xHSSN9_IfX8X_fbhY-lNiU7BbK9AmmbP4Z3vbK7PscmCKRUDXYJn5__zYnOjekO7on58OBJXjfzTNUtJ8-gU_2hg92QA6KRNA2Qb0kZwOzSRB5EnSxm763u2l7epN5uGwfXux3wvKUhjDliAfDzCYacRhlCF04il5qxbaSlGkELry5hSEwFUZmWYsaK2xEU4s-pSVaCWeZ1tywBZjOh7ldBCJSK5XWKQpTcYlvz2QaCcEyw7AbNQGsV9KKfxVkHHEdxNz0Y_-9Alip5BiX9ngfo-eSPnqkAXyrH6MlufSIzu1w7NpIXKsVBmQBfCnEXo_CHE-9cr2jCYWoGziW7skn-W3fs3VT9HGOkieADS_wl2ceH_3o-Iul1zf9Cu86F72T-KR7erwM75vudGJfV7QC06PfY7uKkGmUrHnL-AN-oQ9m
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bTxQxFD5BTIgvCF5gELAaH3xgNtvtZafwhK7rLgoaIgkPJJPOtGUJyyyR3Zjw6zntXGQlJsa3aaZN2zmXfu058xXgXUczxn32lMtVFvOM01hr5WJuM2UNIvok0BcfHsnBCT84FacLsFf_C1PyQzQHbt4ygr_2Bn5t3H0jPx-1qEyUeASPuWwnXqV7x7-5o3jJsoudiViholW0QiGNp246vxg9QJgPEyXvA9iwAvWfwlk99jLx5LI1m2at_PYPWsf_nNwKLFfIlOyXqrQKC7Z4BkuHVez9OZgyjFBX2CXhdP-iILowZDi9IceTsSVYHhYO1ewqhO_Jh8kvOya9Mgy0S1Arybex2SGIOwk62J3Q2hf6gdzkBZz0P_34OIirOxrinCMajJ3NNKIwyhC4cBS81Iq1s5xphC2808YNMBVGOtelxgqb0NyiR-mKbsaZ05ob9hIWi0lh14GI3EqldS4RVHKJs2cyT4RgzjBsRk0Eb2thpdclFUfabGHOR2n4XhFs1mJMK2u8SdFvybB3pBG8aV6jHfngiC7sZObrSFypFW7HIlgrpd70wjxLvfKtkzl9aCp4ju75N8XFKHB1U_RwnpAngvdB3n8feXrweRAeNv696mtY-t7rp1-HR19ewZOOv5o4JBVtwuL058xuIV6aZtvBLu4AYqoOHg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Review+Article%3A+Albumin+and+Its+Role+in+Inflammatory+Bowel+Disease%3A+The+Old%2C+the+New%2C+and+the+Future&rft.jtitle=Journal+of+gastroenterology+and+hepatology&rft.au=Cameron%2C+Karla&rft.au=Nguyen%2C+Anke+L&rft.au=Gibson%2C+David+J&rft.au=Ward%2C+Mark+G&rft.date=2025-04-01&rft.eissn=1440-1746&rft.volume=40&rft.issue=4&rft.spage=808&rft_id=info:doi/10.1111%2Fjgh.16895&rft_id=info%3Apmid%2F39894941&rft.externalDocID=39894941
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0815-9319&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0815-9319&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0815-9319&client=summon